MeiraGTx Holdings plc
MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.79
Price-1.59%
-$0.19
1Y
Price
Market Cap
$1.092b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-10734.1%
EBITDA Margin-12320.2%
Net Profit Margin-3128.0%
Free Cash Flow Margin-10734.1%
EBITDA Margin-12320.2%
Net Profit Margin-3128.0%
Free Cash Flow MarginRevenue
$79.758m
-17.6%
1y CAGR+36.0%
3y CAGR+12.5%
5y CAGREarnings
-$120.533m
-14.1%
1y CAGR-18.3%
3y CAGR-29.4%
5y CAGREPS
-$1.48
+0.5%
1y CAGR+3.7%
3y CAGR-20.7%
5y CAGRBook Value
-$58.130m
$244.655m
Assets$302.785m
Liabilities$87.533m
DebtDebt to Assets
35.8%
-0.6x
Debt to EBITDAFree Cash Flow
-$2.343m
-10.6%
1y CAGR-1.4%
3y CAGR-20.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company